Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

imara inc. - ELVN

ELVN

Close Chg Chg %
20.46 2.20 10.75%

Closed Market

22.66

+2.20 (10.75%)

Volume: 426.52K

Last Updated:

Jan 15, 2025, 4:00 PM EDT

Trade Now

Company Overview: imara inc. - ELVN

ELVN Key Data

Open

$21.10

 Day Range

20.30 - 23.08

52 Week Range

11.02 - 30.01

 Market Cap

$999.66M

Shares Outstanding

48.86M

 Public Float

30.84M

Beta

1.03

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.91

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

233.21K

  

ELVN Performance

1 Week
 
 -5.89%
 
1 Month
 
 -11.62%
 
3 Months
 
 -29.45%
 
1 Year
 
 66.34%
 
5 Years
 
 N/A
 

ELVN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About imara inc. - ELVN

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

ELVN At a Glance

Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder, Colorado 80301
Phone 1-720-647-8519 Revenue 0.00
Industry Biotechnology Net Income -71,584,000.00
Sector Health Technology Employees 46
Fiscal Year-end 12 / 2024
View SEC Filings

ELVN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 2.324
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.873
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.001

ELVN Efficiency

Revenue/Employee N/A
Income Per Employee -1,556,173.913
Receivables Turnover N/A
Total Asset Turnover N/A

ELVN Liquidity

Current Ratio 10.278
Quick Ratio 10.278
Cash Ratio 9.778

ELVN Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -39.351
Return on Equity -42.605
Return on Total Capital -29.071
Return on Invested Capital -42.605

ELVN Capital Structure

Total Debt to Total Equity 0.136
Total Debt to Total Capital 0.136
Total Debt to Total Assets 0.123
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Imara Inc. - ELVN

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
97.00K 99.00K 622.00K 297.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
97.00K 99.00K 622.00K 297.00K
Depreciation
97.00K 99.00K 622.00K 297.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+193.94% +2.06% +528.28% -52.25%
Gross Income
(97.00K) (99.00K) (622.00K) (297.00K)
Gross Income Growth
-193.94% -2.06% -528.28% +52.25%
Gross Profit Margin
- - - -
-
2020 2021 2022 2023 5-year trend
SG&A Expense
41.60M 51.34M 33.65M 83.23M
Research & Development
32.15M 38.44M 18.94M 64.28M
Other SG&A
9.45M 12.90M 14.71M 18.95M
SGA Growth
+72.74% +23.42% -34.46% +147.36%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(41.70M) (51.44M) (34.27M) (83.53M)
Non Operating Income/Expense
338.00K 58.00K 35.85M 11.95M
Non-Operating Interest Income
483.00K 233.00K 943.00K 11.97M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(41.36M) (51.38M) 1.58M (71.58M)
Pretax Income Growth
-76.28% -24.24% +103.07% -4,642.13%
Pretax Margin
- - - -
-
Income Tax
- - - 88.00K
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(41.36M) (51.38M) 1.49M (71.58M)
Minority Interest Expense
- - - -
-
Net Income
(41.36M) (51.38M) 1.49M (71.58M)
Net Income Growth
-76.28% -24.24% +102.90% -4,910.75%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(41.36M) (51.38M) 1.49M (71.58M)
Preferred Dividends
- - - 7.86M
-
Net Income Available to Common
(49.22M) (51.38M) 1.49M (71.58M)
EPS (Basic)
-14.1383 -9.4886 0.2264 -2.0138
EPS (Basic) Growth
-160.32% +32.89% +102.39% -989.49%
Basic Shares Outstanding
3.48M 5.42M 6.57M 35.55M
EPS (Diluted)
-14.1383 -9.4886 0.2264 -2.0138
EPS (Diluted) Growth
-160.32% +32.89% +102.39% -989.49%
Diluted Shares Outstanding
3.48M 5.42M 6.57M 35.55M
EBITDA
(41.60M) (51.34M) (33.65M) (83.23M)
EBITDA Growth
-72.74% -23.42% +34.46% -147.36%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 37.625
Number of Ratings 8 Current Quarters Estimate -0.547
FY Report Date 03 / 2025 Current Year's Estimate -2.282
Last Quarter’s Earnings -0.50 Median PE on CY Estimate N/A
Year Ago Earnings -1.907 Next Fiscal Year Estimate -2.649
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 9 7
Mean Estimate -0.55 -0.57 -2.28 -2.65
High Estimates -0.49 -0.53 -1.70 -1.75
Low Estimate -0.60 -0.61 -2.72 -3.65
Coefficient of Variance -10.07 -7.05 -14.12 -22.23

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 8 6
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Imara Inc. - ELVN

Date Name Shares Transaction Value
Oct 4, 2024 Richard A. Heyman Director 128,585 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.54 per share 3,541,230.90
Oct 4, 2024 Joseph P. Lyssikatos CHIEF SCIENTIFIC OFFICER 1,077,409 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.54 per share 29,671,843.86
Oct 4, 2024 Benjamin Hohl CHIEF FINANCIAL OFFICER 521 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.48 per share 1,292.08
Oct 4, 2024 Samuel S. Kintz PRESIDENT AND CEO; Director 1,048,729 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.54 per share 28,881,996.66
Oct 4, 2024 Benjamin Hohl CHIEF FINANCIAL OFFICER 192,358 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 4, 2024 Benjamin Hohl CHIEF FINANCIAL OFFICER N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.54 per share 0.00
Aug 20, 2024 Richard A. Heyman Director 130,373 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.7 per share 3,089,840.10
Jul 17, 2024 Anish Patel CHIEF OPERATING OFFICER 344,027 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.01 per share 8,604,115.27
Jul 17, 2024 Anish Patel CHIEF OPERATING OFFICER 376,552 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.07 per share 9,440,158.64
Jul 17, 2024 Anish Patel CHIEF OPERATING OFFICER 345,574 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.05 per share 8,656,628.70
Jun 28, 2024 Samuel S. Kintz PRESIDENT AND CEO; Director 1,075,525 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.3 per share 23,984,207.50
Jun 11, 2024 Anish Patel CHIEF OPERATING OFFICER 53,342 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 31, 2024 Benjamin Hohl CHIEF FINANCIAL OFFICER N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.34 per share 0.00
May 31, 2024 Samuel S. Kintz PRESIDENT AND CEO; Director 188,841 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 31, 2024 Samuel S. Kintz PRESIDENT AND CEO; Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.34 per share 0.00
May 31, 2024 Samuel S. Kintz PRESIDENT AND CEO; Director 100 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.57 per share 2,357.00
May 31, 2024 Benjamin Hohl CHIEF FINANCIAL OFFICER 216,870 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2024 OrbiMed Advisors Private Equity Director 7,663,349 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.14 per share 169,666,546.86
May 21, 2024 OrbiMed Advisors Private Equity Director 254,814 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.14 per share 5,641,581.96
May 2, 2024 Joseph P. Lyssikatos CHIEF SCIENTIFIC OFFICER; Director 1,013 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.86 per share 18,092.18

Imara Inc. in the News